肝衰竭预后的临床研究
|
摘要
背景肝衰竭是由多种因素引起的肝细胞大块、亚大块坏死或严重损害,导致其合成、解毒、排泄和生物转化等肝脏功能发生严重障碍或失代偿,出现以黄疸、凝血功能障碍、肝性脑病和腹水等为主要表现的一种临床严重症候群。该病发展迅速,病情凶险,并发症多,病死率高,但潜在可逆转。因此准确判断肝衰竭的预后对实施有效治疗至关重要。目前肝衰竭的治疗缺乏特殊有效的药物和手段。原则上强调早期诊断、早期治疗,针对不同病因采取相应治疗措施,并积极防治各种并发症。对于糖皮质激素在肝衰竭治疗中的应用目前尚存在不同意见。多数学者认为在肝衰竭早期,若病情发展迅速且无严重感染、出血等并发症者,可酌情使用。人工肝支持系统是治疗肝衰竭有效的方法之一,宜用在肝衰竭早、中期;晚期因其并发症多,需慎重。目的探讨影响肝衰竭患者预后的独立危险因素;评价激素治疗及人工肝治疗对各期肝衰竭预后的影响。
方法回顾性分析200例资料完整的肝衰竭病例,收集其临床资料,运用统计学方法,分析不同病因及不同类型肝衰竭患者的预后;筛选出对HBV相关慢加急性(亚急性)肝衰竭预后有影响的独立危险因素;对比Child-Turcotte-Pugh评分系统、MELD评分系统及MELD-Na评分系统对预测肝衰竭预后的价值;评价激素治疗及人工肝治疗对各期肝衰竭预后的影响。
结果
1.HBV引起的肝衰竭组生存率为43.17%,其他原因引起的肝衰竭组生存率为70.59%,两组之间生存率比较存在统计学差异(P<0.05);慢加急性(亚急性)肝衰竭生存率为54.71%,其他类型肝衰竭生存率为36.59%,两组之间生存率比较存在统计学差异(P<0.05)。
2.经Logistic回归筛选影响HBV相关慢加急性(亚急性)肝衰竭预后的独立危险因素为:年龄≥50y、胆酶分离、肝硬化基础、并发症(尤其是肝性脑病、感染、原发性腹膜炎)、CTP评分、MELD-Na评分、TBIL、PTA、Na+及TC。
3.激素治疗组与非激素治疗组比较,在HBV相关慢加急性(亚急性)肝衰竭早期,两组生存率比较有统计学差异,前者生存率高于后者(P<0.05);在HBV相关慢加急性(亚急性)肝衰竭中期,两组生存率比较无统计学差异(P>0.05);两组病程在肝衰竭早期及中期比较均有统计学差异(P>0.05),前者病程明显比后者缩短。人工肝治疗组与非人工肝治疗组比较,在HBV相关慢加急性(亚急性)肝衰竭早期及中期,两组生存率比较有统计学差异(P<0.05);在肝衰竭晚期,两组生存率比较无统计学差异(P>0.05)。
结论年龄≥50y、胆酶分离、肝硬化基础、并发症(尤其是肝性脑病、感染、原发性腹膜炎)、CTP评分、MELD-Na评分、TBIL、PTA、Na+及TC是影响HBV慢加急性(亚急性)肝衰竭患者预后的独立危险因素。激素治疗可以提高早期HBV相关慢加急性(亚急性)肝衰竭患者生存率并缩短病程;人工肝治疗可以提高早期及中期HBV相关慢加急性(亚急性)肝衰竭患者生存率。
Background:Liver failure is caused by many factors of liver cells large, sub-massive necrosis or severe damage, leading to its synthesis, detoxification, excretion and biotransformation of serious disorders such as liver function or decompensation, appear to jaundice, coagulopathy, hepatic encephalopathy and ascites as the main manifestations of a clinically significant syndrome. The disease develops rapidly, the disease risks of complications and high mortality, but the potential can be reversed. Therefore accurately determine the prognosis of liver failure in the implementation of effective treatment is essential. In the current, medical treatment of liver failure lack of effects of drugs and instruments. In principle, we emphasize that early diagnosis and early treatment for different causes of comprehensive treatment to take corresponding measures, and to prevent and treat complications. For glucocorticoids in the treatment of liver failure is currently surviving in the different views. Most scholars believe that early stage of liver failure, if the rapid progression of the disease without serious infection, bleeding and other complications, may be appropriate to use. Artificial liver support system is an effective treatment of liver failure in one of the methods, its application in liver failure early and mid-term is appropriate; advanced liver failure patients can be treated, but more common complications.
Objective: To investigate the prognosis of liver failure were independent risk factors; evaluation of hormone therapy and the artificial liver treatment of liver failure on the prognosis.
Methods: Retrospective analysis of 200 cases of liver failure cases with complete data, collected clinical data, using statistical methods to analyze the different causes and different types of the prognosis of patients with liver failure; screened for HBV-related acute on chronic (sub-acute) prognosis of liver failure independent risk factors affecting; contrast Child-Turcotte-Pugh scoring system, MELD scoring system, and MELD-Na score system for predicting the prognostic value of liver failure; evaluation of hormone therapy and the artificial liver treatment of liver failure on the prognosis.
Results:
1. HBV induced liver failure group survival rate was 43.17%, other causes of liver failure, survival rate was 70.59%, there is significant difference in survival between the two groups (P<0.05); acute on chronic (sub-acute) liver failure survival rate was 54.71%, other types of liver failure, survival rate was 36.59%, there is significant difference in survival between the two groups (P<0.05).
2. Logistic regression selected by the impact of HBV-related acute on chronic (sub-acute) liver failure were independent risk factors: age≥50y, separation of bile enzymes, liver cirrhosis, complications (especially hepatic encephalopathy, infection, primary peritonitis), CTP score, MELD-Na score, TBIL, PTA, Na+ and TC.
3. Hormone therapy group compared with non-hormone therapy in HBV-related acute on chronic (sub-acute) of early liver failure, two groups were significantly different survival rate, survival rate of the former than the latter (P<0.05); in HBV-related slow plus acute (sub-acute) liver failure mid no significant difference in survival the two groups (P> 0.05); two of liver failure in the course of the disease early and mid-term were statistically significant (P>0.05), the former`s course is shorter than the latter. Artificial liver in treatment group compared with non-artificial liver treatment in HBV-related acute on chronic (sub-acute) liver failure early and mid-term, the two groups were significantly different survival (P<0.05); in the late liver failure, two groups of survival There was no significant difference (P>0.05).
Conclusion: Age≥50y, separation of bile enzymes, liver cirrhosis, complications (especially hepatic encephalopathy, infection, primary peritonitis), CTP score, MELD-Na score, TBIL, PTA, Na+ and TC is the impact of HBV slow plus acute (sub-acute) prognosis of patients with liver failure were independent risk factors. Hormone therapy may improve early HBV-related acute on chronic (sub-acute) the survival rate of patients with liver failure and shorten the course of the disease; artificial liver treatment can improve the early and mid-term HBV-related acute on chronic (sub-acute) the survival rate of patients with liver failure.
方法回顾性分析200例资料完整的肝衰竭病例,收集其临床资料,运用统计学方法,分析不同病因及不同类型肝衰竭患者的预后;筛选出对HBV相关慢加急性(亚急性)肝衰竭预后有影响的独立危险因素;对比Child-Turcotte-Pugh评分系统、MELD评分系统及MELD-Na评分系统对预测肝衰竭预后的价值;评价激素治疗及人工肝治疗对各期肝衰竭预后的影响。
结果
1.HBV引起的肝衰竭组生存率为43.17%,其他原因引起的肝衰竭组生存率为70.59%,两组之间生存率比较存在统计学差异(P<0.05);慢加急性(亚急性)肝衰竭生存率为54.71%,其他类型肝衰竭生存率为36.59%,两组之间生存率比较存在统计学差异(P<0.05)。
2.经Logistic回归筛选影响HBV相关慢加急性(亚急性)肝衰竭预后的独立危险因素为:年龄≥50y、胆酶分离、肝硬化基础、并发症(尤其是肝性脑病、感染、原发性腹膜炎)、CTP评分、MELD-Na评分、TBIL、PTA、Na+及TC。
3.激素治疗组与非激素治疗组比较,在HBV相关慢加急性(亚急性)肝衰竭早期,两组生存率比较有统计学差异,前者生存率高于后者(P<0.05);在HBV相关慢加急性(亚急性)肝衰竭中期,两组生存率比较无统计学差异(P>0.05);两组病程在肝衰竭早期及中期比较均有统计学差异(P>0.05),前者病程明显比后者缩短。人工肝治疗组与非人工肝治疗组比较,在HBV相关慢加急性(亚急性)肝衰竭早期及中期,两组生存率比较有统计学差异(P<0.05);在肝衰竭晚期,两组生存率比较无统计学差异(P>0.05)。
结论年龄≥50y、胆酶分离、肝硬化基础、并发症(尤其是肝性脑病、感染、原发性腹膜炎)、CTP评分、MELD-Na评分、TBIL、PTA、Na+及TC是影响HBV慢加急性(亚急性)肝衰竭患者预后的独立危险因素。激素治疗可以提高早期HBV相关慢加急性(亚急性)肝衰竭患者生存率并缩短病程;人工肝治疗可以提高早期及中期HBV相关慢加急性(亚急性)肝衰竭患者生存率。
Background:Liver failure is caused by many factors of liver cells large, sub-massive necrosis or severe damage, leading to its synthesis, detoxification, excretion and biotransformation of serious disorders such as liver function or decompensation, appear to jaundice, coagulopathy, hepatic encephalopathy and ascites as the main manifestations of a clinically significant syndrome. The disease develops rapidly, the disease risks of complications and high mortality, but the potential can be reversed. Therefore accurately determine the prognosis of liver failure in the implementation of effective treatment is essential. In the current, medical treatment of liver failure lack of effects of drugs and instruments. In principle, we emphasize that early diagnosis and early treatment for different causes of comprehensive treatment to take corresponding measures, and to prevent and treat complications. For glucocorticoids in the treatment of liver failure is currently surviving in the different views. Most scholars believe that early stage of liver failure, if the rapid progression of the disease without serious infection, bleeding and other complications, may be appropriate to use. Artificial liver support system is an effective treatment of liver failure in one of the methods, its application in liver failure early and mid-term is appropriate; advanced liver failure patients can be treated, but more common complications.
Objective: To investigate the prognosis of liver failure were independent risk factors; evaluation of hormone therapy and the artificial liver treatment of liver failure on the prognosis.
Methods: Retrospective analysis of 200 cases of liver failure cases with complete data, collected clinical data, using statistical methods to analyze the different causes and different types of the prognosis of patients with liver failure; screened for HBV-related acute on chronic (sub-acute) prognosis of liver failure independent risk factors affecting; contrast Child-Turcotte-Pugh scoring system, MELD scoring system, and MELD-Na score system for predicting the prognostic value of liver failure; evaluation of hormone therapy and the artificial liver treatment of liver failure on the prognosis.
Results:
1. HBV induced liver failure group survival rate was 43.17%, other causes of liver failure, survival rate was 70.59%, there is significant difference in survival between the two groups (P<0.05); acute on chronic (sub-acute) liver failure survival rate was 54.71%, other types of liver failure, survival rate was 36.59%, there is significant difference in survival between the two groups (P<0.05).
2. Logistic regression selected by the impact of HBV-related acute on chronic (sub-acute) liver failure were independent risk factors: age≥50y, separation of bile enzymes, liver cirrhosis, complications (especially hepatic encephalopathy, infection, primary peritonitis), CTP score, MELD-Na score, TBIL, PTA, Na+ and TC.
3. Hormone therapy group compared with non-hormone therapy in HBV-related acute on chronic (sub-acute) of early liver failure, two groups were significantly different survival rate, survival rate of the former than the latter (P<0.05); in HBV-related slow plus acute (sub-acute) liver failure mid no significant difference in survival the two groups (P> 0.05); two of liver failure in the course of the disease early and mid-term were statistically significant (P>0.05), the former`s course is shorter than the latter. Artificial liver in treatment group compared with non-artificial liver treatment in HBV-related acute on chronic (sub-acute) liver failure early and mid-term, the two groups were significantly different survival (P<0.05); in the late liver failure, two groups of survival There was no significant difference (P>0.05).
Conclusion: Age≥50y, separation of bile enzymes, liver cirrhosis, complications (especially hepatic encephalopathy, infection, primary peritonitis), CTP score, MELD-Na score, TBIL, PTA, Na+ and TC is the impact of HBV slow plus acute (sub-acute) prognosis of patients with liver failure were independent risk factors. Hormone therapy may improve early HBV-related acute on chronic (sub-acute) the survival rate of patients with liver failure and shorten the course of the disease; artificial liver treatment can improve the early and mid-term HBV-related acute on chronic (sub-acute) the survival rate of patients with liver failure.
引文
1.王宇明,王小红.肝衰竭的定义及分型诊断探讨[J].中国实用内科杂志, 2005, 25(9): 782-784.
2. Stockmann H B, Hiemstra C A, Marquet R L, et al. Extracorporeal perfusion for the treatment of acute liver failure[J]. Ann Surg, 2000, 231(4): 460-470.
3. Shakil A O, Jones B C, Lee R G, et al. Prognostic value of abdominal CT scanning and hepatic histopathology in patients with acute liver failure[J]. Dig Dis Sci, 2000; 45(2): 334–339.
4.惠国,郜桂菊,陈涛,等.影响重型病毒性肝炎患者预后的危险因素研究[J].临床肝胆病杂志, 2002.18(5): 297-299.
5.单晶,徐瑞平,丁小君,等.重型病毒性肝炎患者预后模型的临床应用分析[J].中国危重病急救医学, 2005, 17(10):586-588.
6. Blci AT. Medical therapy of brain edema in fulminant hepatic failure[J]. Hepatology, 2000, 32(3): 666-669.
7. Lee WM. Acute liver failure in United States. Semin Liver Dis[J], 2003, 23(3): 217-226.
8. Yoshiba M, Sekiyama K, Inoue K, et al. Accurate prediction of fulminant hepatic failure in severe acute viral hepatitis: multicenter study[J]. J Castroenterol, 2002, 7(11): 916-921.
9. Bernal W, Donaldson N, Wyncoll D, et al. Blood lactate as an early predictor of outcome in paracetamol-induced acute liver failure: a cohort study[J]. Lancet, 2002, 16, 359(9306): 558-563.
10. Schmidt LE, Larsen FS. Prognostic implications of hyperlactatemia, multiple organ failure, and systemic inflammatory response syndrome in patients with acetaminopheninduced acute liver failure[J]. Crit Care Med, 2006, 34(2): 337-343.
11.周和龙,何生松,杨小明,等.重型病毒性肝炎预后的临床分析[J].临床消化病杂志. 2002, 14(6): 245-247.
12.张南,王宇明,邓国红,等.慢性重型肝炎患者的预后因素分析及预后模型的建立[J].中华肝脏病杂志. 2005. 13(10): 730-733.
13.赖宁,郭树华,张大志,等.重型肝炎预后单因素分析与评估系统研究[J].中华肝脏病杂志, 2005, 13(8): 586-589.
14.孙晓羽,甄真,重型肝炎预后评分系统及其临床应用现状[J].临床荟萃, 2010, 25(23): 2106-2108.
15. Daliana P B, Christian Mt, Flavio L F, et al. The Multiple Organ Dysfunction Score (MODS) versus the Sequential Organ Failure Assessment (SOFA) score in outcome prediction[J]. Intensive Care Med, 2002, 28: 1619–1624.
16. Radha K. D, Sanjay J, Uma M, Early indicators of prognosis in fulminant hepatic failure: An assessment of the Model for End-Stage Liver Disease (MELD) and King's College Hospital Criteria[J]. Liver Transplantation, 2007, 13(6): 814-821.
17. Patrick S. K, Russell H. W, Michael M, et al.A model to predict survival in patients with end‐stage liver disease[J]. Hepatology, 2001, 33(2): 464–470.
18. Li Zhou, Pei Ling Dong, Hui Guo Ding. Comparison scoring model of severe viral hepatitis and model of end stage liver disease for the prognosis of patients with liver failure in China[J]. World J Gastroenterol, 2007, 13(21): 2999-3002.
19.甄秀梅,罗光汉.糖皮质激素在乙型肝炎肝功能衰竭治疗中的应用[J].中华临床感染病杂志, 2010, 3(2): 126-128.
20.中华医学会感染病学分会肝衰竭与人工肝学组,中华医学会肝病学分会重型肝病与人工肝学组.肝衰竭诊疗指南[J].中华肝脏病杂志, 2006, 14(6): 643-646.
1.中华医学会感染病学分会肝衰竭与人工肝学组,中华医学会肝病学分会重型肝病与人工肝学组.肝衰竭诊疗指南[J].中华肝脏病杂志, 2006, 14(6): 643-646.
2.贾林,张美华.肝性脑病的定义命名诊断和定量标准修订方案的新进展[J].世界华人消化杂志, 2003, 11(12): 2008-2010.
3.孙晓羽,甄真,重型肝炎预后评分系统及其临床应用现状[J].临床荟萃, 2010, 25(23): 2106-2108.
4. Patrick S. K, Russell H. W, Michael M,et al.A model to predict survival in patients with end‐stage liver disease[J]. Hepatology, 2001, 33(2): 464–470.
5.石虹.双谱指数对有症状的肝性脑病分级的敏感度和特异度:多中心、单盲、验证研究[J].肝脏, 2008, 13(2): 153.
6.贾林,张美华.肝性脑病的定义、命名、诊断和定量标准修订方案的新进展[J].世界华人消化杂志, 2003, 11(12): 2008-2010.
7.曹立滨,杨晓丽,马凤霞.肝肾综合征的诊断、治疗和发病机制研究[J].中国医药指南, 2009, 7(8): 45-46.
8.周智,赖宁,张全海. 186例晚期肝病患者并发原发性腹膜炎的诊断与治疗[J].中华肝脏病杂志, 2004, 12(6): 350-352.
9.江学成.危重疾病严重程度评分临床应用及意义[J].中国危重病急救医学, 2000, 12(4): 195-197.
10.连鄂湘,吴婉芬,石裕明,等.慢性病毒性肝炎不同病因与预后的关系[J].中华实验和临床病毒学杂志, 1999, 13(4): 355-357.
11. Fujiwara K, Mochida S. Indications and criteria for liver transplantation for fulminant hepatic failure[J]. J Gastroenterol, 2002, 37(13): 74-77.
12. Propst A , Propst T, Zangerl G, et al. Prognosis and life expectancy in chronic liver disease[J]. Digestive Diseases and Sciences, 1995, 40(8): 1805-1815.
13. Alessandria C, Ozdogan O, Guevara M. MELD score and clinical type predict prognosis in hepatorenal syndrome: relevance to liver transplantation[J]. Hepatology, 2005, 41(6): 1282-1289.
14.赖宁,郭树华,张大志,等.重型肝炎预后单因素分析与评估系统研究[J].中华肝脏病杂志, 2005, 13(8): 586-589.
15.李保森,邹正升,孙颖,等.各型重型肝炎的临床特征及影响其预后的危险因素分析[J].传染病信息, 2007, 20(3): 151-154.
16.丁惠国,郜桂菊,陈涛,等.影响重型病毒性肝炎患者预后的危险因素研究[J].临床肝胆病杂志, 2002, 18(5): 297-299.
17. Acharya SK, Dasarathy S, Irshad M. Prospective study of plasma fibronectin in fulminant hepatitis: association with infection and mortality[J]. J Hepatol, 1995, 23(1): 8-13.
18.于卫红,段忠辉,冯岩梅,等.慢性重型肝炎病原学、病变基础、性别、年龄分布于预后相关性的探讨[J].中国全科医学, 2006, 9(19): 1600-1601.
19.阎兰菊,李蒙军,许青田.影响86例重型肝炎预后因素分析[J].世界感染杂志, 2005, 5(1): 87.
20.陈菊梅,邹正升.重型乙型肝炎肝衰竭的预防和控制[J].传染病信息, 2008, 21(2): 65-67.
21.焦运,李玉芳,刘秀华. 105例慢性重症肝炎生化及凝血功能检测与预后分析[J].宁夏医学院学报, 2004, 26(2): 106-107.
22.李永刚,杨大国.“胆酶分离”作为判断重度肝损害指标的再探讨[J].中西医结合肝病杂志, 1995, 5(1): 15-17.
23.赵敏. 97例慢性重症肝炎生存分析[J].临床肝胆病杂志, 2000, 16(1): 51.
24.宋国培.肝功能-血清酶学检测的临床意义[J].临床肝脏病杂志, 2003, 8(6): 195-197.
25.蒋玉兰,访亚伟.胆固醇、胆碱酯酶在重症肝炎中的临床意义[J].中国现代临床医药, 2007, 6(1): 66.
26.朱雄鹰. 64例重型肝炎死亡患者凝血酶原时间、前白蛋白、胆固醇、胆碱酯酶观察的临床意义[J].临床医学, 2003, 11(11): 58.
27.刘文芝,冯继红,金萍,等.重型肝炎患者的实验室检测与预后的关系[J].中国实验诊断学, 2010, 14(5): 752-753.
28.周建,叶俊茂. MELD与PT对乙型肝炎慢加急性肝衰竭患者短期预后的评价[J].中华临床感染病杂志, 2008, 1(4): 207-209.
29.杨清,龚作炯,张全荣.慢性重型病毒性肝炎低钠血症的治疗探讨[J].临床肝胆病杂志. 2002, 18(3): 191-192.
30.李保森,邹正生,陈菊梅,等.慢性重型肝炎并发症与预后的关系[J].中国医师杂志, 2002, 4(10): 1096-1098.
31. Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease[J]. Hepatology, 2001, 33(2): 464-470.
32. Bernuau J, Rueff B, Benhamou JP. Fulminant and subfulminant liver failure: definitions and causes[J]. Semin Liver Dis, 1986, 6(2): 97-106.
33.吴云忠,赵凤林,张春泽,等.慢性重型乙型肝炎转归相关因素及抗病毒治疗研究[J].中华实验和临床病毒学杂志, 2007, 6(21): 120-122.
34.蒋忠胜,江建宁. CTP和MELD评分预测慢性重型肝炎预后的临床价值[J].中国危重病急救医学, 2007, 19(7): 412-415.
35.唐长华,李志彬,刘芳,等.四种评分模型对慢性重型乙型肝炎患者短期预后的比较[J].临床肝胆病杂志, 2010, 26(6): 591-593.
36. Malinehoe M, Kamath P S, Gordon F D, et al. A model to predict poor survival in patients undergoing transjugular intraliver portosystemic shunts[J]. Hepatology, 2000, 31(4): 864-871.
37. Ruf AE, Kremers WK, Chavez LL, et al. Addition of serum sodium into the MELD score predicts waiting list mortality better than MELD alone[J]. Liver Transpl, 2005, 11(3): 336-343.
38. Beggins SW, Kim WR, Terrault NA, et al. Evidence-based incorporation of serum sodium concentration into MELD[J]. Gastroenterology, 2006, 130(6): 1652-1660.
39. Selcuk H, Uruc I, Temel MA, et al. Factors prognostic of survival in patients awaiting liver transplantation for end-stage liver diseases[J]. Digestive Diseases and Sciences, 2007, 52(11): 3217-3223.
40.徐微,谢志萍,裴豪,等.人工肝支持系统治疗慢性重型肝炎34例临床研究[J].中国实用内科杂志, 2004, 24(1):48-49.
41. Poyck PP, Wilk AC, Van Hoeven TV, et al. Evaluation of new immortalized human fetal liver cell line (cBAL111) for application inbioartificial liver[J]. Journal of Hepatology, 2008, 48 (2): 266-275.
42.甄秀梅,罗光汉.糖皮质激素在乙型肝炎肝功能衰竭治疗中的应用[J].中华临床感染病杂志. 2010, 3(2): 126-128.
43.李映菊,汪煜华,彭忠田.糖皮质激素治疗早期重型肝炎最佳方案初探[J].华南大学学报·医学版,2010, 38(1): 80-83.
44. Matsumoto K, Miyake Y, Miyatake H, et al. A combination treatment of entecavir and early-phase corticosteroid in severe exacerbation of chronic hepatitis B [J]. World J Gastroenterol, 2009, 15: 1650-652.
45. Zhang XQ, Jiang L, You JP, et al. Efficacy of short-term dexamethasone therapy in acute-on-chronic pre-liver failure [J]. Hepatology Research, 2011, 41: 46-53.
1.中华医学会感染病学分会肝衰竭与人工肝学组,中华医学会肝病学分会重型肝病与人工肝学组.肝衰竭诊疗指南[J].中华肝脏病杂志, 2006, 14(6): 643-646.
2.叶一农,高志良.乙型肝炎肝衰竭发生机制中的三重打击[J].传染病信息, 2009, 22(5): 276-279.
3.覃小敏,宁琴.重型肝炎发病的分子机制研究进展[J].国外医学·流行病学传染病学分册, 2004, 31(3): 150-153.
4.孙艳玲,赵景民,周光德,等.重型肝炎发病时相及临床病理特征的研究[J].中华实验和临床病毒学杂志, 2003, 17(3): 270-273.
5.王麟士.重型病毒性肝炎的发病机制与治疗概况[J].临床荟萃. 2006, 21(6): 455-457.
6.王宇明,汤影子.重型乙型肝炎发病机制研究进展[J].传染病信息, 2008, 21(2): 68-70.
7.王静艳,穆挂玲,刘沛,等,乙型重型肝炎基因变异与免疫异常的关系[J].中华传染病杂志, 2001, 19(2):73-76.
8. Imamura T, Yokosuka O, Kurihara T, et al. Distribution of hepatitis B viral genotypes and mutations in the Core promoter and precore regions in acute forms of liver disease in patients from Chiba, Japan[J]. Gut, 2003, 52(11): 1630-1637.
9. Hou J, Lin Y, Waters J, et al. Detection and significance of a Gl862T variant of hepatitis B virus in Chinese patients with fulminant hepatitis[J]. J Gen Virol, 2002, 83(9): 2291-2298.
10. Sainokami S, Abe K, Sato A, et al. Initial load of hepatitis B virus (HBV), its changing
1.中华医学会感染病学分会肝衰竭与人工肝学组,中华医学会肝病学分会重型肝病与人工肝学组.肝衰竭诊疗指南[J].中华肝脏病杂志, 2006, 14(6): 643-646.
2.叶一农,高志良.乙型肝炎肝衰竭发生机制中的三重打击[J].传染病信息, 2009, 22(5): 276-279.
3.覃小敏,宁琴.重型肝炎发病的分子机制研究进展[J].国外医学·流行病学传染病学分册, 2004, 31(3): 150-153.
4.孙艳玲,赵景民,周光德,等.重型肝炎发病时相及临床病理特征的研究[J].中华实验和临床病毒学杂志, 2003, 17(3): 270-273.
5.王麟士.重型病毒性肝炎的发病机制与治疗概况[J].临床荟萃. 2006, 21(6): 455-457.
6.王宇明,汤影子.重型乙型肝炎发病机制研究进展[J].传染病信息, 2008, 21(2): 68-70.
7.王静艳,穆挂玲,刘沛,等,乙型重型肝炎基因变异与免疫异常的关系[J].中华传染病杂志, 2001, 19(2):73-76.
8. Imamura T, Yokosuka O, Kurihara T, et al. Distribution of hepatitis B viral genotypes and mutations in the Core promoter and precore regions in acute forms of liver disease in patients from Chiba, Japan[J]. Gut, 2003, 52(11): 1630-1637.
9. Hou J, Lin Y, Waters J, et al. Detection and significance of a Gl862T variant of hepatitis B virus in Chinese patients with fulminant hepatitis[J]. J Gen Virol, 2002, 83(9): 2291-2298.
10. Sainokami S, Abe K, Sato A, et al. Initial load of hepatitis B virus (HBV), its changingMicrobes Infect, 2009, 11(4): 515-523.
20. Zhang Z, Zou ZS, Fu JL, et al. Severe dendritic cell perturbation is actively involved in the pathogenesis of acute-on-chronic hepatitis B liver failure[J]. J Hepatol, 2008, 49(3): 396-406.
21. Malhi H, Gores GJ. Cellular and molecular mechanisms of liver injury[J]. Gastroenterology, 2008, 134(6): 1641-1654.
22. Guidotti LG, Chisari FV. Immunobiology and pathogenesis of viral hepatitis[J]. Annu Rev Pathol, 2006, 1: 23-61.
23. Noriaki S, Kazuhide Y, Marcelo J. K, et al. HBcAg-Specific CD8 T Cells Play an Important Role in Virus Suppression, and Acute Flare-Up Is Associated with the Expansion of Activated Memory T Cells[J]. Journal of Clinical Immunology, 2003, 23(3): 223-232.
24.吴引伟,文剑,赵伟,等.系统检测慢性乙型肝炎患者外周血淋巴细胞免疫表型的临床意义[J].世界华人消化杂志, 2006, 14(34): 3321-3325.
25. Ludger L, Silvia C, Jan R, et al. Imbalanced Intrahepatic Expression of Interleukin 12, Interferon Gamma, and Interleukin 10 in Fulminant Hepatitis B[J]. Hepatology, 2002, 36(4): 1001-1008.
26. Kimura K, Ando K, Tomita E, et al. Elevated intracellular IFN-gamma levels in circulating CD8+ lymphocytes in patients with fulminant hepatitis[J]. J Hepatol, 1999, 3l (4): 579-583.
27.郑亚江,高月球,王灵台.慢性乙型肝炎重症化机制的探讨[J].中西医结合肝病杂志, 2005, 15(5): 316-318.
28. Leifeld L, Nattermann J, Fielenbach M, et al.Intrahepatic activation of caspases in human fulminant hepatic failure [J]. Liver Int, 2006, 26(7): 872-879.
29. Mita A, Hashikura Y, Tagawa Y, et al. Expression of Fas ligand by hepatic macrophages in patients with fulminant hepatic failure[J]. Am J Gastroenterol, 2005, 100(11): 2551-2559.
30. Hou W, Liu KZ, Li MW, et al. Effect of IFN alpha-2a on Fas expression and apoptosis rate of peripheral blood cytotoxic T cells in patients with hepatitis B[J]. Hepatobiliary Pancreat Dis Int, 2005, 4(3): 403-405.
31. Ryo K, Kamogawa Y, Ikeda I, et al. Significance of Fas antigen-mediated apoptosis in human fulminant hepatic failure[J]. Am J Gastrcenterol, 2000, 95(8): 2047-2055.
32. Rivero M, Crespo J, Fabrega E, et al. Apoptosis mediated by the Fas system in the fulminant hepatitis by hepatitis B virus[J]. J Viral Hepat, 2002, 9(2): 107-113.
33. Radziewicz H, Hanson HL, Ahmed R, et al. Unraveling the role of PD-1/PD-L interactions in persistent hepatotropic infections: potential for therapeutic application? [J]. Gastroenterology, 2008, 134(7): 2168-2171.
34. Zhang Z, Zhang JY, Wherry EJ, et al. Dynamic programmed death 1 expression by virus-specific CD8 T cells correlates with the outcome of acute hepatitis B[J]. Gastroenterology, 2008, 134(7): 1938-1949.
35.游晶,庄林,马永良,等.慢性乙型肝炎的Th细胞亚群及相关细胞因子网络失衡[J].世界华人消化杂志, 2007, 15(8): 791-799.
36. Rutherford AE, Hynan LS, Borges CB, et al. Serum apoptosis markers in acute liver failure: a pilot study[J]. Clin Gastroenterol Hepatol, 2007, 5(12): 1477-1483.
37. Nagaki M, Moriwaki H. Implication of cytokines: roles of tumor necrosis factor-alpha in liver injury [J]. Hepatol Res, 2008, 38(S1): S19-S28.
38. Zou Z, Li B, Xu D, et al. Imbalanced intrahepatic cytokine expression of interferon-gamma, tumor necrosis factor-alpha, and interleukin-10 in patients with acute-on-chronic liver failure associated with hepatitis B virus infection[J]. J Clin Gastroenterol, 2009, 43(2): 182-190.
39. Nagaki M, Iwai H, Naiki T, et al. High levels of senrum interleukin-10 and Tumor necrosis factor are associated with fatality infulminant hepatitis[J]. J Infect Dis, 2000, 182: 1103-1l08.
40. Ohta K, Sekimoto M, Sato M, et al. Indispensable role for TNF-αand IFN-γat theeffector phase of liver injury mediated by Thl cells specific to hepatitis B virus surface antigen[J]. J Immunol, 2000, 165: 956-961.
41. Jin X, Zimmers TA, Perez EA, et al. Paradoxical effects of short-and long-term interleukin-6 exposure on liver injury and repair [J]. Hepatology, 2006, 43(3): 474-484.
42.张耿林,高志良.乙型肝炎相关慢加急性肝衰竭的免疫学特征及治疗策略[J].中国病毒病杂志, 2011, 1(1): 5-8.
43.叶钒,邱梦标,王农荣,等.乙型肝炎患者不同时期体液免疫水平检测研究分析[J].中国医药报道, 2010, 7(7): 168.
44.迟丽娜,黄俊佩.重型肝炎患者IgA、IgG、IgM、C3检测的临床意义[J].中西医结合肝病杂志, 2002, 12(4): 220.
45.姚安延,邓丽玲,王黎明.重型肝炎患者免疫球蛋白及补体C3的变化[J].检验医学与临床, 2005, 2(6): 268.
46. Xing T, Li L, Cao H, et al. Altered immune function of monocytes in different stages of patients with acute on chronic liver failure[J]. Clin Exp Immunol, 2007, 147(1): 184-188.
47.饶珊珊,李建英.缺血性肝炎[J].世界华人消化杂志, 2008, 16(35): 3974-3978.
48. Nakano Y, Kondo T, Matsuo R, et al. Platelet dynamics in the early phase of postischemic liver in vivo [J]. J Surg Res, 2008, 149(2): 192-198.
49. Kotoh K, Enjoji M, Kato M, et al. A new parameter using serum lactate dehydrogenase and alanine aminotransferase level is useful for predicting the prognosis of patients at an early stage of acute liver injury: a retrospective study[J]. Comp Hepatol, 2008, 7(1): 6.
50. Langdale LA, Hoagland V, Benz W, et al. Suppressor of cytokine signaling expression with increasing severity of murine hepatic is chemia-reperfusion injury[J]. J Hepatol, 2008, 49(2): 198-206.
51. Nardo B, Montalti R, Puviani L, et al. Portal vein oxygen supply through a liverextracorporeal device to treat acute liver failure in swine induced by subtotal hepatectomy: preliminary data[J]. Transplant Proc, 2006, 38(4): 1190-1192.
52.罗瑞虹,崇雨田,赵志新,等.前列腺素E1治疗重型病毒性肝炎的Meta分析[J].中山大学学报(医学科学版), 2005, 26(4): 476-480.
53.林英,陈晓理,应明英.凝血系统与炎症细胞因子的相互联系[J].中国输血杂志, 2003, 16(1): 7-10.
54. Uesugi T, Froh M, Arteel GE, et al. Role of lipopolysaccharide binding protein in early alcohol-induced liver injury in mice[J]. J Immunol, 2002, 168(6): 2963-2969.
55. Zang GQ, Zhou XQ, Yu H, et al. Effect of hepatocyte apoptosis induced by TNF-alpha on acute severe hepatitis in mouse models[J]. World J Gastroenterol, 2000, 6(5): 688-692.
2. Stockmann H B, Hiemstra C A, Marquet R L, et al. Extracorporeal perfusion for the treatment of acute liver failure[J]. Ann Surg, 2000, 231(4): 460-470.
3. Shakil A O, Jones B C, Lee R G, et al. Prognostic value of abdominal CT scanning and hepatic histopathology in patients with acute liver failure[J]. Dig Dis Sci, 2000; 45(2): 334–339.
4.惠国,郜桂菊,陈涛,等.影响重型病毒性肝炎患者预后的危险因素研究[J].临床肝胆病杂志, 2002.18(5): 297-299.
5.单晶,徐瑞平,丁小君,等.重型病毒性肝炎患者预后模型的临床应用分析[J].中国危重病急救医学, 2005, 17(10):586-588.
6. Blci AT. Medical therapy of brain edema in fulminant hepatic failure[J]. Hepatology, 2000, 32(3): 666-669.
7. Lee WM. Acute liver failure in United States. Semin Liver Dis[J], 2003, 23(3): 217-226.
8. Yoshiba M, Sekiyama K, Inoue K, et al. Accurate prediction of fulminant hepatic failure in severe acute viral hepatitis: multicenter study[J]. J Castroenterol, 2002, 7(11): 916-921.
9. Bernal W, Donaldson N, Wyncoll D, et al. Blood lactate as an early predictor of outcome in paracetamol-induced acute liver failure: a cohort study[J]. Lancet, 2002, 16, 359(9306): 558-563.
10. Schmidt LE, Larsen FS. Prognostic implications of hyperlactatemia, multiple organ failure, and systemic inflammatory response syndrome in patients with acetaminopheninduced acute liver failure[J]. Crit Care Med, 2006, 34(2): 337-343.
11.周和龙,何生松,杨小明,等.重型病毒性肝炎预后的临床分析[J].临床消化病杂志. 2002, 14(6): 245-247.
12.张南,王宇明,邓国红,等.慢性重型肝炎患者的预后因素分析及预后模型的建立[J].中华肝脏病杂志. 2005. 13(10): 730-733.
13.赖宁,郭树华,张大志,等.重型肝炎预后单因素分析与评估系统研究[J].中华肝脏病杂志, 2005, 13(8): 586-589.
14.孙晓羽,甄真,重型肝炎预后评分系统及其临床应用现状[J].临床荟萃, 2010, 25(23): 2106-2108.
15. Daliana P B, Christian Mt, Flavio L F, et al. The Multiple Organ Dysfunction Score (MODS) versus the Sequential Organ Failure Assessment (SOFA) score in outcome prediction[J]. Intensive Care Med, 2002, 28: 1619–1624.
16. Radha K. D, Sanjay J, Uma M, Early indicators of prognosis in fulminant hepatic failure: An assessment of the Model for End-Stage Liver Disease (MELD) and King's College Hospital Criteria[J]. Liver Transplantation, 2007, 13(6): 814-821.
17. Patrick S. K, Russell H. W, Michael M, et al.A model to predict survival in patients with end‐stage liver disease[J]. Hepatology, 2001, 33(2): 464–470.
18. Li Zhou, Pei Ling Dong, Hui Guo Ding. Comparison scoring model of severe viral hepatitis and model of end stage liver disease for the prognosis of patients with liver failure in China[J]. World J Gastroenterol, 2007, 13(21): 2999-3002.
19.甄秀梅,罗光汉.糖皮质激素在乙型肝炎肝功能衰竭治疗中的应用[J].中华临床感染病杂志, 2010, 3(2): 126-128.
20.中华医学会感染病学分会肝衰竭与人工肝学组,中华医学会肝病学分会重型肝病与人工肝学组.肝衰竭诊疗指南[J].中华肝脏病杂志, 2006, 14(6): 643-646.
1.中华医学会感染病学分会肝衰竭与人工肝学组,中华医学会肝病学分会重型肝病与人工肝学组.肝衰竭诊疗指南[J].中华肝脏病杂志, 2006, 14(6): 643-646.
2.贾林,张美华.肝性脑病的定义命名诊断和定量标准修订方案的新进展[J].世界华人消化杂志, 2003, 11(12): 2008-2010.
3.孙晓羽,甄真,重型肝炎预后评分系统及其临床应用现状[J].临床荟萃, 2010, 25(23): 2106-2108.
4. Patrick S. K, Russell H. W, Michael M,et al.A model to predict survival in patients with end‐stage liver disease[J]. Hepatology, 2001, 33(2): 464–470.
5.石虹.双谱指数对有症状的肝性脑病分级的敏感度和特异度:多中心、单盲、验证研究[J].肝脏, 2008, 13(2): 153.
6.贾林,张美华.肝性脑病的定义、命名、诊断和定量标准修订方案的新进展[J].世界华人消化杂志, 2003, 11(12): 2008-2010.
7.曹立滨,杨晓丽,马凤霞.肝肾综合征的诊断、治疗和发病机制研究[J].中国医药指南, 2009, 7(8): 45-46.
8.周智,赖宁,张全海. 186例晚期肝病患者并发原发性腹膜炎的诊断与治疗[J].中华肝脏病杂志, 2004, 12(6): 350-352.
9.江学成.危重疾病严重程度评分临床应用及意义[J].中国危重病急救医学, 2000, 12(4): 195-197.
10.连鄂湘,吴婉芬,石裕明,等.慢性病毒性肝炎不同病因与预后的关系[J].中华实验和临床病毒学杂志, 1999, 13(4): 355-357.
11. Fujiwara K, Mochida S. Indications and criteria for liver transplantation for fulminant hepatic failure[J]. J Gastroenterol, 2002, 37(13): 74-77.
12. Propst A , Propst T, Zangerl G, et al. Prognosis and life expectancy in chronic liver disease[J]. Digestive Diseases and Sciences, 1995, 40(8): 1805-1815.
13. Alessandria C, Ozdogan O, Guevara M. MELD score and clinical type predict prognosis in hepatorenal syndrome: relevance to liver transplantation[J]. Hepatology, 2005, 41(6): 1282-1289.
14.赖宁,郭树华,张大志,等.重型肝炎预后单因素分析与评估系统研究[J].中华肝脏病杂志, 2005, 13(8): 586-589.
15.李保森,邹正升,孙颖,等.各型重型肝炎的临床特征及影响其预后的危险因素分析[J].传染病信息, 2007, 20(3): 151-154.
16.丁惠国,郜桂菊,陈涛,等.影响重型病毒性肝炎患者预后的危险因素研究[J].临床肝胆病杂志, 2002, 18(5): 297-299.
17. Acharya SK, Dasarathy S, Irshad M. Prospective study of plasma fibronectin in fulminant hepatitis: association with infection and mortality[J]. J Hepatol, 1995, 23(1): 8-13.
18.于卫红,段忠辉,冯岩梅,等.慢性重型肝炎病原学、病变基础、性别、年龄分布于预后相关性的探讨[J].中国全科医学, 2006, 9(19): 1600-1601.
19.阎兰菊,李蒙军,许青田.影响86例重型肝炎预后因素分析[J].世界感染杂志, 2005, 5(1): 87.
20.陈菊梅,邹正升.重型乙型肝炎肝衰竭的预防和控制[J].传染病信息, 2008, 21(2): 65-67.
21.焦运,李玉芳,刘秀华. 105例慢性重症肝炎生化及凝血功能检测与预后分析[J].宁夏医学院学报, 2004, 26(2): 106-107.
22.李永刚,杨大国.“胆酶分离”作为判断重度肝损害指标的再探讨[J].中西医结合肝病杂志, 1995, 5(1): 15-17.
23.赵敏. 97例慢性重症肝炎生存分析[J].临床肝胆病杂志, 2000, 16(1): 51.
24.宋国培.肝功能-血清酶学检测的临床意义[J].临床肝脏病杂志, 2003, 8(6): 195-197.
25.蒋玉兰,访亚伟.胆固醇、胆碱酯酶在重症肝炎中的临床意义[J].中国现代临床医药, 2007, 6(1): 66.
26.朱雄鹰. 64例重型肝炎死亡患者凝血酶原时间、前白蛋白、胆固醇、胆碱酯酶观察的临床意义[J].临床医学, 2003, 11(11): 58.
27.刘文芝,冯继红,金萍,等.重型肝炎患者的实验室检测与预后的关系[J].中国实验诊断学, 2010, 14(5): 752-753.
28.周建,叶俊茂. MELD与PT对乙型肝炎慢加急性肝衰竭患者短期预后的评价[J].中华临床感染病杂志, 2008, 1(4): 207-209.
29.杨清,龚作炯,张全荣.慢性重型病毒性肝炎低钠血症的治疗探讨[J].临床肝胆病杂志. 2002, 18(3): 191-192.
30.李保森,邹正生,陈菊梅,等.慢性重型肝炎并发症与预后的关系[J].中国医师杂志, 2002, 4(10): 1096-1098.
31. Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease[J]. Hepatology, 2001, 33(2): 464-470.
32. Bernuau J, Rueff B, Benhamou JP. Fulminant and subfulminant liver failure: definitions and causes[J]. Semin Liver Dis, 1986, 6(2): 97-106.
33.吴云忠,赵凤林,张春泽,等.慢性重型乙型肝炎转归相关因素及抗病毒治疗研究[J].中华实验和临床病毒学杂志, 2007, 6(21): 120-122.
34.蒋忠胜,江建宁. CTP和MELD评分预测慢性重型肝炎预后的临床价值[J].中国危重病急救医学, 2007, 19(7): 412-415.
35.唐长华,李志彬,刘芳,等.四种评分模型对慢性重型乙型肝炎患者短期预后的比较[J].临床肝胆病杂志, 2010, 26(6): 591-593.
36. Malinehoe M, Kamath P S, Gordon F D, et al. A model to predict poor survival in patients undergoing transjugular intraliver portosystemic shunts[J]. Hepatology, 2000, 31(4): 864-871.
37. Ruf AE, Kremers WK, Chavez LL, et al. Addition of serum sodium into the MELD score predicts waiting list mortality better than MELD alone[J]. Liver Transpl, 2005, 11(3): 336-343.
38. Beggins SW, Kim WR, Terrault NA, et al. Evidence-based incorporation of serum sodium concentration into MELD[J]. Gastroenterology, 2006, 130(6): 1652-1660.
39. Selcuk H, Uruc I, Temel MA, et al. Factors prognostic of survival in patients awaiting liver transplantation for end-stage liver diseases[J]. Digestive Diseases and Sciences, 2007, 52(11): 3217-3223.
40.徐微,谢志萍,裴豪,等.人工肝支持系统治疗慢性重型肝炎34例临床研究[J].中国实用内科杂志, 2004, 24(1):48-49.
41. Poyck PP, Wilk AC, Van Hoeven TV, et al. Evaluation of new immortalized human fetal liver cell line (cBAL111) for application inbioartificial liver[J]. Journal of Hepatology, 2008, 48 (2): 266-275.
42.甄秀梅,罗光汉.糖皮质激素在乙型肝炎肝功能衰竭治疗中的应用[J].中华临床感染病杂志. 2010, 3(2): 126-128.
43.李映菊,汪煜华,彭忠田.糖皮质激素治疗早期重型肝炎最佳方案初探[J].华南大学学报·医学版,2010, 38(1): 80-83.
44. Matsumoto K, Miyake Y, Miyatake H, et al. A combination treatment of entecavir and early-phase corticosteroid in severe exacerbation of chronic hepatitis B [J]. World J Gastroenterol, 2009, 15: 1650-652.
45. Zhang XQ, Jiang L, You JP, et al. Efficacy of short-term dexamethasone therapy in acute-on-chronic pre-liver failure [J]. Hepatology Research, 2011, 41: 46-53.
1.中华医学会感染病学分会肝衰竭与人工肝学组,中华医学会肝病学分会重型肝病与人工肝学组.肝衰竭诊疗指南[J].中华肝脏病杂志, 2006, 14(6): 643-646.
2.叶一农,高志良.乙型肝炎肝衰竭发生机制中的三重打击[J].传染病信息, 2009, 22(5): 276-279.
3.覃小敏,宁琴.重型肝炎发病的分子机制研究进展[J].国外医学·流行病学传染病学分册, 2004, 31(3): 150-153.
4.孙艳玲,赵景民,周光德,等.重型肝炎发病时相及临床病理特征的研究[J].中华实验和临床病毒学杂志, 2003, 17(3): 270-273.
5.王麟士.重型病毒性肝炎的发病机制与治疗概况[J].临床荟萃. 2006, 21(6): 455-457.
6.王宇明,汤影子.重型乙型肝炎发病机制研究进展[J].传染病信息, 2008, 21(2): 68-70.
7.王静艳,穆挂玲,刘沛,等,乙型重型肝炎基因变异与免疫异常的关系[J].中华传染病杂志, 2001, 19(2):73-76.
8. Imamura T, Yokosuka O, Kurihara T, et al. Distribution of hepatitis B viral genotypes and mutations in the Core promoter and precore regions in acute forms of liver disease in patients from Chiba, Japan[J]. Gut, 2003, 52(11): 1630-1637.
9. Hou J, Lin Y, Waters J, et al. Detection and significance of a Gl862T variant of hepatitis B virus in Chinese patients with fulminant hepatitis[J]. J Gen Virol, 2002, 83(9): 2291-2298.
10. Sainokami S, Abe K, Sato A, et al. Initial load of hepatitis B virus (HBV), its changing
1.中华医学会感染病学分会肝衰竭与人工肝学组,中华医学会肝病学分会重型肝病与人工肝学组.肝衰竭诊疗指南[J].中华肝脏病杂志, 2006, 14(6): 643-646.
2.叶一农,高志良.乙型肝炎肝衰竭发生机制中的三重打击[J].传染病信息, 2009, 22(5): 276-279.
3.覃小敏,宁琴.重型肝炎发病的分子机制研究进展[J].国外医学·流行病学传染病学分册, 2004, 31(3): 150-153.
4.孙艳玲,赵景民,周光德,等.重型肝炎发病时相及临床病理特征的研究[J].中华实验和临床病毒学杂志, 2003, 17(3): 270-273.
5.王麟士.重型病毒性肝炎的发病机制与治疗概况[J].临床荟萃. 2006, 21(6): 455-457.
6.王宇明,汤影子.重型乙型肝炎发病机制研究进展[J].传染病信息, 2008, 21(2): 68-70.
7.王静艳,穆挂玲,刘沛,等,乙型重型肝炎基因变异与免疫异常的关系[J].中华传染病杂志, 2001, 19(2):73-76.
8. Imamura T, Yokosuka O, Kurihara T, et al. Distribution of hepatitis B viral genotypes and mutations in the Core promoter and precore regions in acute forms of liver disease in patients from Chiba, Japan[J]. Gut, 2003, 52(11): 1630-1637.
9. Hou J, Lin Y, Waters J, et al. Detection and significance of a Gl862T variant of hepatitis B virus in Chinese patients with fulminant hepatitis[J]. J Gen Virol, 2002, 83(9): 2291-2298.
10. Sainokami S, Abe K, Sato A, et al. Initial load of hepatitis B virus (HBV), its changingMicrobes Infect, 2009, 11(4): 515-523.
20. Zhang Z, Zou ZS, Fu JL, et al. Severe dendritic cell perturbation is actively involved in the pathogenesis of acute-on-chronic hepatitis B liver failure[J]. J Hepatol, 2008, 49(3): 396-406.
21. Malhi H, Gores GJ. Cellular and molecular mechanisms of liver injury[J]. Gastroenterology, 2008, 134(6): 1641-1654.
22. Guidotti LG, Chisari FV. Immunobiology and pathogenesis of viral hepatitis[J]. Annu Rev Pathol, 2006, 1: 23-61.
23. Noriaki S, Kazuhide Y, Marcelo J. K, et al. HBcAg-Specific CD8 T Cells Play an Important Role in Virus Suppression, and Acute Flare-Up Is Associated with the Expansion of Activated Memory T Cells[J]. Journal of Clinical Immunology, 2003, 23(3): 223-232.
24.吴引伟,文剑,赵伟,等.系统检测慢性乙型肝炎患者外周血淋巴细胞免疫表型的临床意义[J].世界华人消化杂志, 2006, 14(34): 3321-3325.
25. Ludger L, Silvia C, Jan R, et al. Imbalanced Intrahepatic Expression of Interleukin 12, Interferon Gamma, and Interleukin 10 in Fulminant Hepatitis B[J]. Hepatology, 2002, 36(4): 1001-1008.
26. Kimura K, Ando K, Tomita E, et al. Elevated intracellular IFN-gamma levels in circulating CD8+ lymphocytes in patients with fulminant hepatitis[J]. J Hepatol, 1999, 3l (4): 579-583.
27.郑亚江,高月球,王灵台.慢性乙型肝炎重症化机制的探讨[J].中西医结合肝病杂志, 2005, 15(5): 316-318.
28. Leifeld L, Nattermann J, Fielenbach M, et al.Intrahepatic activation of caspases in human fulminant hepatic failure [J]. Liver Int, 2006, 26(7): 872-879.
29. Mita A, Hashikura Y, Tagawa Y, et al. Expression of Fas ligand by hepatic macrophages in patients with fulminant hepatic failure[J]. Am J Gastroenterol, 2005, 100(11): 2551-2559.
30. Hou W, Liu KZ, Li MW, et al. Effect of IFN alpha-2a on Fas expression and apoptosis rate of peripheral blood cytotoxic T cells in patients with hepatitis B[J]. Hepatobiliary Pancreat Dis Int, 2005, 4(3): 403-405.
31. Ryo K, Kamogawa Y, Ikeda I, et al. Significance of Fas antigen-mediated apoptosis in human fulminant hepatic failure[J]. Am J Gastrcenterol, 2000, 95(8): 2047-2055.
32. Rivero M, Crespo J, Fabrega E, et al. Apoptosis mediated by the Fas system in the fulminant hepatitis by hepatitis B virus[J]. J Viral Hepat, 2002, 9(2): 107-113.
33. Radziewicz H, Hanson HL, Ahmed R, et al. Unraveling the role of PD-1/PD-L interactions in persistent hepatotropic infections: potential for therapeutic application? [J]. Gastroenterology, 2008, 134(7): 2168-2171.
34. Zhang Z, Zhang JY, Wherry EJ, et al. Dynamic programmed death 1 expression by virus-specific CD8 T cells correlates with the outcome of acute hepatitis B[J]. Gastroenterology, 2008, 134(7): 1938-1949.
35.游晶,庄林,马永良,等.慢性乙型肝炎的Th细胞亚群及相关细胞因子网络失衡[J].世界华人消化杂志, 2007, 15(8): 791-799.
36. Rutherford AE, Hynan LS, Borges CB, et al. Serum apoptosis markers in acute liver failure: a pilot study[J]. Clin Gastroenterol Hepatol, 2007, 5(12): 1477-1483.
37. Nagaki M, Moriwaki H. Implication of cytokines: roles of tumor necrosis factor-alpha in liver injury [J]. Hepatol Res, 2008, 38(S1): S19-S28.
38. Zou Z, Li B, Xu D, et al. Imbalanced intrahepatic cytokine expression of interferon-gamma, tumor necrosis factor-alpha, and interleukin-10 in patients with acute-on-chronic liver failure associated with hepatitis B virus infection[J]. J Clin Gastroenterol, 2009, 43(2): 182-190.
39. Nagaki M, Iwai H, Naiki T, et al. High levels of senrum interleukin-10 and Tumor necrosis factor are associated with fatality infulminant hepatitis[J]. J Infect Dis, 2000, 182: 1103-1l08.
40. Ohta K, Sekimoto M, Sato M, et al. Indispensable role for TNF-αand IFN-γat theeffector phase of liver injury mediated by Thl cells specific to hepatitis B virus surface antigen[J]. J Immunol, 2000, 165: 956-961.
41. Jin X, Zimmers TA, Perez EA, et al. Paradoxical effects of short-and long-term interleukin-6 exposure on liver injury and repair [J]. Hepatology, 2006, 43(3): 474-484.
42.张耿林,高志良.乙型肝炎相关慢加急性肝衰竭的免疫学特征及治疗策略[J].中国病毒病杂志, 2011, 1(1): 5-8.
43.叶钒,邱梦标,王农荣,等.乙型肝炎患者不同时期体液免疫水平检测研究分析[J].中国医药报道, 2010, 7(7): 168.
44.迟丽娜,黄俊佩.重型肝炎患者IgA、IgG、IgM、C3检测的临床意义[J].中西医结合肝病杂志, 2002, 12(4): 220.
45.姚安延,邓丽玲,王黎明.重型肝炎患者免疫球蛋白及补体C3的变化[J].检验医学与临床, 2005, 2(6): 268.
46. Xing T, Li L, Cao H, et al. Altered immune function of monocytes in different stages of patients with acute on chronic liver failure[J]. Clin Exp Immunol, 2007, 147(1): 184-188.
47.饶珊珊,李建英.缺血性肝炎[J].世界华人消化杂志, 2008, 16(35): 3974-3978.
48. Nakano Y, Kondo T, Matsuo R, et al. Platelet dynamics in the early phase of postischemic liver in vivo [J]. J Surg Res, 2008, 149(2): 192-198.
49. Kotoh K, Enjoji M, Kato M, et al. A new parameter using serum lactate dehydrogenase and alanine aminotransferase level is useful for predicting the prognosis of patients at an early stage of acute liver injury: a retrospective study[J]. Comp Hepatol, 2008, 7(1): 6.
50. Langdale LA, Hoagland V, Benz W, et al. Suppressor of cytokine signaling expression with increasing severity of murine hepatic is chemia-reperfusion injury[J]. J Hepatol, 2008, 49(2): 198-206.
51. Nardo B, Montalti R, Puviani L, et al. Portal vein oxygen supply through a liverextracorporeal device to treat acute liver failure in swine induced by subtotal hepatectomy: preliminary data[J]. Transplant Proc, 2006, 38(4): 1190-1192.
52.罗瑞虹,崇雨田,赵志新,等.前列腺素E1治疗重型病毒性肝炎的Meta分析[J].中山大学学报(医学科学版), 2005, 26(4): 476-480.
53.林英,陈晓理,应明英.凝血系统与炎症细胞因子的相互联系[J].中国输血杂志, 2003, 16(1): 7-10.
54. Uesugi T, Froh M, Arteel GE, et al. Role of lipopolysaccharide binding protein in early alcohol-induced liver injury in mice[J]. J Immunol, 2002, 168(6): 2963-2969.
55. Zang GQ, Zhou XQ, Yu H, et al. Effect of hepatocyte apoptosis induced by TNF-alpha on acute severe hepatitis in mouse models[J]. World J Gastroenterol, 2000, 6(5): 688-692.